PRME
Prime Medicine, Inc. Common Stock
NASDAQ: PRME · HEALTHCARE · BIOTECHNOLOGY
$3.53
-4.34% today
Updated 2026-04-29
Market cap
$666.47M
P/E ratio
—
P/S ratio
143.88x
EPS (TTM)
$-1.35
Dividend yield
—
52W range
$1 – $7
Volume
2.5M
Prime Medicine, Inc. Common Stock (PRME) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $5.21M | $0.00 | $5.21M | $0.00 | $2.98M | $4.63M |
| Revenue growth (YoY) | — | — | -100.0% | — | -100.0% | — | +55.3% |
| Cost of revenue | $2.76M | $2.98M | $4.86M | $12.01M | $4.65M | $6.13M | $7.32M |
| Gross profit | $-2.76M | $2.23M | $-4.86M | $-12.01M | $-4.65M | $2.98M | $-2.69M |
| Gross margin | — | 42.8% | — | -230.6% | — | 100.0% | -58.1% |
| R&D | $920000.00 | $2.98M | $70.55M | $86.72M | $147.91M | $155.29M | $160.64M |
| SG&A | $3.76M | $3.16M | $13.92M | $29.82M | $43.39M | $50.16M | $52.35M |
| Operating income | $-2.17M | $-932000.00 | $-84.47M | $-116.54M | $-204.79M | $-202.47M | $-208.35M |
| Operating margin | — | -17.9% | — | -2236.9% | — | -6787.4% | -4498.1% |
| EBITDA | $-2.17M | $-889000.00 | $-83.91M | $-114.32M | $-186.64M | $-196.34M | $-195.76M |
| EBITDA margin | — | -17.1% | — | -2194.2% | — | -6581.9% | -4226.2% |
| EBIT | $-8.69M | $-932000.00 | $-84.47M | $-116.54M | $-191.29M | $-202.47M | $-201.14M |
| Interest expense | — | $10.26M | $81.77M | $12.13M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.53M | $-3.41M | $-165.37M | $-121.82M | $-198.13M | $-195.88M | $-201.14M |
| Net income growth (YoY) | — | -34.8% | -4749.5% | +26.3% | -62.6% | +1.1% | -2.7% |
| Profit margin | — | -65.5% | — | -2338.2% | — | -6566.6% | -4342.4% |